Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-based calcineurin inhibitor–free immunosuppression in non-heart-beating donor kidney recipients
2007-002763-27Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in kidney allograft rejection (2 arms), sponsored by Erasmus MC. Primary endpoints: eGFR at 12 months post-randomization and Biopsy-proven acute rejection rate. Started Aug 2007; status: active.
02
Drugs
sirolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2007-002763-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002763-27.